Takeda Financial Statements From 2010 to 2024
| TKDA Stock | EUR 12.70 0.10 0.79% |
Check Takeda Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Takeda Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Takeda financial statements analysis is a perfect complement when working with Takeda Pharmaceutical Valuation or Volatility modules.
Takeda |
Takeda Pharmaceutical Company Return On Equity Analysis
Takeda Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Takeda Pharmaceutical Return On Equity | 0.0477 |
Most of Takeda Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Takeda Pharmaceutical has a Return On Equity of 0.0477. This is 100.2% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all Germany stocks is 115.39% lower than that of the firm.
Takeda Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Takeda Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Takeda Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Takeda Pharmaceutical competition to find correlations between indicators driving Takeda Pharmaceutical's intrinsic value. More Info.Takeda Pharmaceutical is currently regarded as top stock in return on equity category among its peers. It is rated third in return on asset category among its peers reporting about 0.52 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Takeda Pharmaceutical is roughly 1.93 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Takeda Pharmaceutical's earnings, one of the primary drivers of an investment's value.About Takeda Pharmaceutical Financial Statements
Takeda Pharmaceutical stakeholders use historical fundamental indicators, such as Takeda Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Takeda Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Takeda Pharmaceutical's assets and liabilities are reflected in the revenues and expenses on Takeda Pharmaceutical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Takeda Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. TAKEDA PHARM operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Takeda Stock
Takeda Pharmaceutical financial ratios help investors to determine whether Takeda Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Takeda with respect to the benefits of owning Takeda Pharmaceutical security.